Global Computer Aided Detection (CAD) Market - 2022-2029

Market Overview

The global computer aided detection (CAD) market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Computer-Aided Detection (CAD) is a software system that uses various imaging modalities such as computed tomography, tomosynthesis, and magnetic resonance imaging to help detect various types of cancers and neurological and cardiovascular disorders.

Market Dynamics

The factors influencing the global computer aided detection (CAD) market are technological advancements and the increasing prevalence of various disorders.

The technological advancements are expected to drive the global computer aided detection (CAD) market in the forecast period

Digital impressions and models and the use of virtual articulators are all advantages of CAD/CAM technology. Complete dentures and removable partial denture frameworks are among the current applications of the design software. 5 axis milling units provide the most accuracy in restoration fabrication. Although 3D printing technology has been used in dentistry, it is limited to polymers and does not include ceramics. Optical impressions will be replaced in the future by ultrasound impressions using ultrasonic waves, which can penetrate the gingiva non-invasively without retraction cords and are unaffected by fluids. Computer-aided detection (CAD) technology has established itself as a primary line of defence in the cancer treatment process, allowing clinicians to pinpoint suspicious tissue more quickly. CAD, which is about a decade old, has become a notable cancer-detecting weapon thanks to advancements in computer technology. Because of its ability to detect cancer at an earlier stage in screening, CAD first gained popularity in breast applications.

Furthermore, CAD manufacturers have begun to extend the technology's reach into chest, lung, and colon applications. Early on, some observers predicted that computer-aided design (CAD) would revolutionise breast imaging to the point where it would supplant traditional visualisation techniques. Some have even suggested that the "D" in CAD could be used in place of more traditional visualisation techniques, despite the fact that diagnosis and detection are two different things. More of the diagnostic interpretation process will be supported by computer-aided detection. More services will be provided by CAD applications, such as better defining why a feature should be noted, calculating the BI-RADS score, and automatically generating reports.

The limitations associated with CAD are expected to hamper the market growth

CAD's position in the imaging and visualization segment of the cancer treatment process, particularly in mammography - was influenced by several performance-related challenges. For instance, CAD for mammoths failed to detect small masses under 1.5 mm, identify and prevent architectural distortions, and reduce the number of false positives. The high rate of false-positive marks when using currently available computer-aided detection (CAD) systems is a significant disadvantage. A count of these marks on each image, which is false positives per image, can be used to evaluate the utility of CAD (FPPI). False-positive results can cause too much "noise" for the interpreting radiologist. They may result in unnecessary tests and biopsies. As a result, radiologists frequently complain about high FPPI when reviewing CAD marks. In the United States, false-positive recalls and workups cost about $4 billion per year. Diagnostic mammogram workups alone cost 1.62 billion dollars. These false-positive screening mammograms cause unnecessary anxiety in the patient and may lead to an unnecessary biopsy. Another issue is the overall cost of CAD. It's prohibitively expensive for smaller facilities like outpatient mammography and physician practices. The federal Centers for Medicare and Medicaid Services (CMS) have decided to reduce the procedure and technology reimbursement.

COVID-19 Impact Analysis

Currently, determining the presence of viral nucleic acid using a nucleic acid kit for reverse transcription-polymerase chain reaction (RT-PCR) is the primary method for diagnosing COVID-19. Medical imaging methods (such as chest X-ray (CXR) and computer tomography (CT)) can play a significant role in the diagnosis of COVID-19 because some cases have imaging features, but nucleic acid detection has hysteresis. Furthermore, nucleic acid testing can only determine if a patient has COVID-19. However, it cannot assess the condition, whereas medical imaging can. The accurate monitoring of disease progression is a critical component of disease management for COVID-19 patients. Imaging can monitor suspected cases, such as close contact with COVID-19 patients with a negative nucleic acid test. Doctors can use a computer-aided diagnosis (CAD) system based on CT scans to diagnose COVID-19 and better understand disease progression. Hence, the computer aided detection market is expected to positively impact increasing demand.

Segment Analysis

Based on application, breast cancer segment is expected to dominate the market growth

The increasing prevalence of breast cancer and the growing application of CAD in breast cancer diagnosis is expected to drive the market growth. In 2020, 2.3 million women worldwide were diagnosed with breast cancer, with 685 000 deaths. As of 2020, 7.8 million women had been diagnosed with breast cancer in the previous five years, making it the most common cancer in the world. Researchers have been studying computer-aided detection (CAD) systems in mammography for many years. These systems were created to assist radiologists in detecting breast cancer signs. Computer-aided detection (CAD) is expected to become a more important tool for radiologists in the early detection of breast cancer. In the United States, breast cancer is one of the leading causes of death. The most effective tool for early detection of breast cancer is screening mammography. However, mammogram interpretation can be difficult due to the variable appearance of normal breast tissue. In dense breasts, overlapping tissue structures can mask lesions, making detection difficult. Computer-aided detection systems (CAD) have been developed. Microcalcifications, masses, and architectural distortions are all signs of breast cancer. CAD research has been to find early warning signs of these manifestations.

Geographical Analysis

North America region is expected to hold the largest market share in the global computer aided detection (CAD) market

The increasing prevalence of cancer and healthcare expenditure in this region is expected to drive market growth in the forecast period.

According to CDC, in 2018, there were 1,708,921 new cancer cases reported in the United States, and 599,265 cancer-related deaths. 436 new cancer cases were reported for every 100,000 people, with 149 people dying from cancer. The increasing number of companies manufacturing devices with computer aided detection is expected to drive market growth. For instance, Senographe(R) 2000D full-field digital mammography system is a significant step forward to help thousands of women gain access to new breast cancer detection technology.

According to the National Cancer Institute of Canada, two out of every 19 Canadian women are expected to develop breast cancer during their lifetime. Furthermore, breast cancer is the most diagnosed cancer in women in Canada. The GE Senographe 2000D full-field digital mammography system, developed by GE Medical Systems, a division of General Electric Company, is revolutionising patient care by cutting patient exam time in half, allowing medical institutions to screen a larger number of patients. Digital Computer-Aided Detection is now available in Europe, and GE Medical executives expect the Senographe 2000D to be equipped with the technology in Canada.

Competitive Landscape

With company mergers, collaborations, and product launches, the global computer aided detection (CAD) market is highly competitive. Some of the key players in the market are FUJIFILM Holdings Corporation, Hologic, Inc., iCAD Inc., Koninklijke Philips N.V., Siemens, Canon Medical Systems Corporation, IBM, Riverain Technologies., Median Technologies, Hitachi Ltd.

FUJIFILM Holdings Corporation

Overview: Fujifilm is a Japanese multinational conglomerate based in Tokyo, Japan, that operates in photography, optics, office and medical electronics, biotechnology, and chemicals. The company was founded in 1934.

Product Portfolio: Fujifilm Digital Mammography CAD is an excellent detection aid. This CAD system uses proprietary algorithms to detect areas on the breast image that may indicate cancer. CAD stands for Computer-Aided Diagnosis.

Why Purchase the Report?

Visualize the composition of the global computer aided detection (CAD) market segmentation by imaging modalities, by application, and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global computer aided detection (CAD) market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global computer aided detection (CAD) market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global computer aided detection (CAD) market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers